A61K 40/34
Antigenic peptides
A61K40/34 (Antigenic peptides) appears on 48 US grants and 155 published applications in this corpus.
Search patents in A61K- Granted patents
- 48
- Published applications
- 155
- Assignees
- 105
- Inventors
- 396
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 8 |
| 2003 | 2 | 5 |
| 2004 | 4 | 6 |
| 2005 | 1 | 0 |
| 2006 | 1 | 3 |
| 2007 | 1 | 2 |
| 2008 | 0 | 11 |
| 2009 | 1 | 12 |
| 2010 | 4 | 0 |
| 2011 | 1 | 5 |
| 2012 | 4 | 2 |
| 2013 | 2 | 0 |
| 2014 | 2 | 3 |
| 2015 | 0 | 2 |
| 2016 | 1 | 1 |
| 2017 | 1 | 7 |
| 2018 | 2 | 1 |
| 2019 | 0 | 6 |
| 2020 | 1 | 4 |
| 2021 | 1 | 2 |
| 2022 | 5 | 14 |
| 2023 | 3 | 23 |
| 2024 | 5 | 14 |
| 2025 | 3 | 13 |
| 2026 | 2 | 11 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions, devices and methods for inducing immune responses to infectious agents16 Jun 2026US 12,653,888 B2Sigilon Therapeutics, Inc.
- Compositions and methods for targeting mutant RAS27 Jan 2026US 12,533,409 B2The Trustees of the University of Pennsylvania
- Oncolytic virus vaccine and drug for treating tumors by combining oncolytic virus vaccine with immune cells16 Dec 2025US 12,496,337 B2Joint Biosciences (Sh) Ltd.
- Truncated epiderimal growth factor receptor (EGFRt) for transduced t cell selection23 Sep 2025US 12,421,294 B2City of Hope
- Systems targeting PSMA and CA925 Mar 2025US 12,257,304 B2Arsenal Biosciences, Inc.
- Switch receptors1 Oct 2026US 2026/0295042 A1Hoffmann-La Roche Inc.
- Immune tolerance induction for auto-immune diseases through platelet targeted gene therapy involving myelin oligodendrocyte glycoprotein (mog) polypeptide3 Sep 2026US 2026/0256843 A1The Medical College of Wisconsin, Inc.
- Modified mrna for multicell transformation6 Aug 2026US 2026/0224703 A1Tuhura Biosciences, Inc.
- T cells with increased expression of malic enzyme 1 and uses thereof in cancer therapy25 Jun 2026US 2026/0176650 A1Mayo Foundation for Medical Education and Research
- Methods and compositions for tumor immunotherapy using patient-derived immune cell products and il-15 superagonists14 May 2026US 2026/0130995 A1Nant Holdings IP, LLC
Most cited
By later US patents
- Maturation of dendritic cells with immune response modifying compounds206US 6,558,951 B13M Innovative Properties Company · 2003
- Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection117US 8,802,374 B2City of Hope · 2014
- Compositions and methods for identifying antigens which elicit an immune response89US 6,500,641 B1Wake Forest University School of Medicine · 2002
- Compositions and methods for the therapy and diagnosis of breast cancer20US 6,680,197 B2Corixa Corporation · 2004
- Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection18US 9,580,685 B2City of Hope · 2017